DICE Therapeutics Inc.

3 trials Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

6 Countries active

3 Unique IMPs

100% Results reported

Phase II

Phase I (Other)

Phase II: 2 Phase I (Other): 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Top IMPs

DC-806 2 DC-806, [14C] DC-806 1 LY4100511 1

All trials

3 total

A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended

2024-512207-39-00 Phase II 4 countries LY4100511
A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended

2022-502249-90-00 Phase II 5 countries DC-806
A PHASE 1 STUDY TO ASSESS THE EXCRETION BALANCE, PHARMACOKINETICS, AND METABOLISM OF [14C] DC 806 IN HEALTHY MALE PARTICIPANTS. Ended

2023-505367-36-00 Phase I (Other) 1 country DC-806; DC-806, [14C] DC-806

Showing 1–3 of 3 trials

← All sponsors A–Z